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Impression cytology (IC) is a technique which permits the retrieval of the outermost layer of ocular surface
cells via the use of various types of filters. It is a minimally invasive method of evaluating human conjunc-
tival epithelial cell morphology in the diagnosis of dry eye disease, a common and distressing disorder
associated with ageing, contact lens wear, autoimmune disorders and refractive (LASIK) surgery. IC may
also be utilized in the diagnosis of other ocular diseases, such as keratoconus and thyroid orbitopathy.
More recently, IC has been utilized for the subsequent investigation of gene and protein expression of
conjunctival cells in order to identify novel diagnostic biomarkers and to further our understanding of the
mechanisms underlying ocular surface disease. This review will therefore examine the literature concern-
ing the role of IC in identifying cellular markers of eye disease, systemic diseases with ocular involvement
and potential novel therapeutic targets.
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Impression cytology (IC) is a minimally invasive method of evaluating human ocular surface cells and is considered
as the ‘gold standard’ technique for assessing cell morphology. Introduced by Thatcher et al. [1] and Egbert et al. [2],
IC is an easy-to-use technique of directly retrieving (mainly conjunctival) cells, using various filter types which
are gently applied to exposed (interpalpebral) conjunctival surfaces. The filters used include cellulose acetate [3],
polycarbonate (Biopore, Millipore UK Ltd, Watford, UK) [4], nitrocellulose [5] or polyethersulfone (PES) [6] which
are gently applied to exposed (interpalpebral) conjunctival surfaces. Recently, a more standardized tool for IC
sampling has been introduced (Figures 1 & 2). The Eyeprim is a new single-use PES filter sampling medical
device for retrieval of conjunctival cells (Opia Technologies, France) and a recent study by Lopez-Miguel et al. [7]
performed an analysis of this tool versus the traditional IC method (PES). On a cohort of 20 healthy individuals,
they extracted and compared RNA from both devices and found no significant differences in the mean yield (p
≥ 0.45), the total RNA amount (μg), or the amount normalized to membrane area [7]. Although an earlier study
of the Eyeprim [8], suggested that it recovered more cells than traditional IC, Lopez-Miguel et al. [7] did not observe
differences in the RNA collected between this device and PES.
Historically, IC has been used to analyze pathological changes to conjunctival cells for indicators of squamous
metaplasia in ocular surface disease (OSD) [9]. More recently, however, researchers have used IC to examine specific
markers of inflammation, for example, HLA-DR, ICAM-1 and CD8 [10–12], and to examine novel biomarkers
of dry eye disease (DED). The latter is performed in an attempt to understand the mechanisms underpinning
DED pathophysiology and is now feasible, due to vast improvements in the assay sensitivities for gene and
protein examination [13]. As a result, IC membranes can be subsequently analyzed using techniques such as
immunofluorescent staining, flow cytometry, multiplex bead immunoassays and real-time PCR (qPCR) [14–17]. For
example, recent research by our group on RNA extracted from Eyeprims of DED subjects demonstrated adequate
RNA levels to perform qPCR for a number of inflammatory markers, including p38 MAPK-α, IL-1β, IL-8, MCP-1
and MMP-9 [18]. This study showed that, in subjects with DED, all five proinflammatory genes were significantly
upregulated, compared with normal subjects (p < 0.001).
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Figure 1. Conjunctival impression cytology sampling
using the Eyeprim device.
Figure 2. Fluorescein staining of the conjunctiva.
(A) Immediately after Eyeprim sampling (red dots show
outer limits of staining) and (B) at 24 h post-sampling (no
fluorescein staining visible). Note the re-epithelialisation
of the ocular surface within 1 day of cell retrieval.
It is therefore anticipated that biomarkers identified by IC will serve as future novel diagnostic tools (for better
stratification of patients), and in measuring outcomes of targeted clinical therapies. Together, it is hoped that the use
of IC-validated biomarkers may help to develop a more personalized approach to diagnosing and treating ocular,
and possibly some systemic diseases.
Impression cytology & ocular surface disease
As mentioned, IC has traditionally been used to identify morphological changes (e.g., squamous metaplasia), in
OSD, primarily in DED. However, subsequent IC studies have assessed other OSDs and have noted substantial
conjunctival goblet cell loss and changes to epithelial cell size. For example, in 1986 Wittpenn et al. [19] first
demonstrated reduced goblet cell numbers and increased epithelial cell size of the conjunctiva in vitamin A
deficiency-induced xerophthalmia in children, and suggested a role for IC in early detection of this condition. Since
then, various groups have used IC to assess the effects of DED therapies on the ocular surface, including the effects
of preservatives in ophthalmic medications and autologous serum [20–22]. A summary of potential OSD-related
biomarkers using IC can be found in Table 1.
Dry eye disease & squamous metaplasia
In DED, squamous metaplasia is defined as the transition from a nonkeratinized, stratified epithelium (e.g., con-
junctiva and cornea) to a nonsecretory, keratinized epithelium. In the conjunctival epithelium, squamous metaplasia
presents as a continuum of changes, including reduction/loss of goblet cells (hence mucin deficiency) and gradual
alterations of nongoblet epithelial cells (i.e., increased keratinization and stratification), as well as cellular enlarge-
ment and an increased cytoplasmic/nuclear ratio [23]. Squamous metaplasia can thus be considered as altered
differentiation and this process is thought to be initiated by diminished aqueous tear production, resulting in tear
fluid hyperosmolarity.
1136 Biomark. Med. (2017) 11(12) future science group
Biomarkers of ocular surface disease using impression cytology Review
Table 1. A summary of potential biomarkers of dry eye disease and ocular surface disease using im-
pression cytology.




SS-DE McNamara et al. (2014)
Jirsova et al. (2014)
[47]
[22]
EGFR, IL-6, IL-9, NAMPT, CD8 oGvHD Cocho et al. (2015)
Eberwein et al. (2013)
[43]
[12]
IL-1, IL-8, MMP-9 TGF-1 Blepharitis and MGD Zhang et al. (2015) [39]
HLA-DR, ICAM-1,
MUC1, MUC2, MUC4, MUC5AC,
IL-6
Generic DED/ OSD Aronni et al. (2006)
Corrales et al. (2011)
López-Garcı́a et al. (2016)





Eotaxin-1, -2, & -3, Hemopexin
CCL-20
Ocular allergies: VKC, AKC Shoji et al. (2009)
Pong et al. (2011)
Inada et al. (2014)







Thyroid orbitopathy Pawlowski et al. (2014)
Hsu et al. (2016)
[62]
[15]
AKC: Atopic keratoconjunctivitis; DED: Dry eye disease; IC: Impression cytology; MGD: Meibomian gland dysfunction; oGvHD: Ocular graft-versus-host
disease; OSD: Ocular surface disease; SS-DE: Sjögren’s syndrome-dry eye; VKC: Vernal keratoconjunctivitis.
Dry eye disease & inflammatory markers
HLA-DR
As well as assessing morphological changes in squamous metaplasia, IC can be used to quantify inflammatory
markers, such as the MHC Class II antigen HLA-DR. HLA-DR was found to be induced by exposure of conjunctival
cells to hyperosmolarity [24]. HLA-DR is thus considered a proinflammatory marker, and it is specifically upregulated
in patients with severe DED. In 1992, Baudouin et al. showed that IC could specifically detect HLA-DR expression
in human conjunctival cells [11]. Then, in 1997 Baudouin demonstrated HLA-DR quantification via IC, using
flow cytometry [25]. More recently, Yafawi et al. [26] further demonstrated the usefulness of HLA-DR (via IC) as
a biomarker of OSD, in a validation study to assess its reliability by IC and flow cytometry. To assess specificity,
12 donors were divided into groups; normal, mild DED, moderate DED or severe DED (three per group). The
authors reported higher HLA-DR expression in moderate DED (19.8% over normals) and severe DED (23.3%
over normals), while mild DED showed a 10.8% increase over normal samples. The authors concluded that HLA-
DR could serve as an inflammatory biomarker which correlated with DED severity, and that IC was a simple and
reproducible technique [26].
It should be noted that quantitative HLA-DR detection by IC has been used in several DED clinical trials.
Indeed, Epstein et al. [27] used a multicenter study to establish a standard operating procedure for utilizing IC and
HLA-DR as an objective DED inflammatory biomarker, using duplicate samples from dry eye and normal subjects.
The study found that expression of HLA-DR expression may be a reliable and objective inflammatory biomarker
for use in multicenter clinical trial studies. More recently, Brignole-Baudouin [16] undertook an investigation of
HLA-DR alongside clinical signs and symptoms, using data from 311 patients with moderate-to-severe DED from
three clinical studies. In DED, clinical signs and symptoms rarely correlate, making diagnosis more difficult for the
clinician. The authors reported a significant correlation between the clinical test of corneal fluorescein staining and
HLA-DR (r = 0.26 and 0.30, respectively), as well as with a tear production test (Schirmer’s test; r = -0.20), albeit
to a lesser degree. This group concluded that, although further work is necessary, HLA-DR expression may serve
as a useful measure of eye surface inflammation and DED.
Furthermore, in terms of using IC and HLA-DR to assess DED therapies, recent research analyzed 20 aqueous
deficient dry eye subjects who were exposed to low humidity, then compared the efficacy of artificial tears versus
0.1% dexamethasone [28]. IC membranes were analyzed for changes in HLA-DR RNA expression by digital PCR
and this group noted less irritation in those treated with dexamethasone versus artificial tear use, as well as reduced
HLA-DR expression (both p = 0.01) [28]. Topical cyclosporine (CsA) significantly reduced HLA-DR expression
in patients with DED [29], and other work has demonstrated that oral supplementation of omega-3 and omega-6
fatty acids decreased HLA-DR expression in conjunctival cells of DED patients [30]. These studies indicate how IC
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may be used, not only in determining levels of ocular surface inflammation, but also in monitoring the outcome of
various therapies.
ICAM-1
Similar to HLA-DR, ICAM-1 (CD54) is upregulated on the conjunctival epithelium in ocular surface inflammation
and could represent a potential biomarker detectable by IC [31]. Although far fewer studies have been performed
on this molecule than HLA-DR with regards to IC and DED, research in 2006 assessed ICAM-1 in subjects with
severe dry eye [32]. They reported increased ICAM-1 expression (by immunofluorescent staining) in dry eye subjects
versus controls. Moreover in dry eye, ICAM-1 staining had an inverse relation to number of goblet cells (p < 0.01;
rho = -0.852) and tear production (Schirmer’s test; p < 0.01; rho = -0.926). Once again, a combined approach
of IC and inflammatory biomarkers can be used to good effect in assessing dry eye.
Dry eye disease & mucins
Mucins are the glycoproteins secreted by conjunctival goblet cells, which form the innermost layer of the tear
film, the mucous layer. With the increasing improvements in sensitivities of assays, qPCR has been utilized to
ascertain mucin changes at the gene level in IC membranes. For example, Corrales et al. [33] undertook a prospective
study of patients with moderate-to-severe dry eye compared with healthy subjects. Following installation of topical
anesthetic, two halves of a PES filter were applied to the superior and superotemporal bulbar conjunctiva of the most
affected eye. RNA extraction and qPCR were performed for MUC1, MUC2, MUC4, and MUC5AC and MUC7,
and the former four genes were found to be significantly lower in the conjunctiva of dry eye patients than controls
(all p < 0.0001). The authors surmised that, of the genes assessed, MUC1 demonstrated the highest specificity and
sensitivity (87.5 and 83.3%, respectively), suggesting its potential as a diagnostic marker of DED [33]. More recent
work on mucin expression in DED [14] also used this technique (qPCR) to assess the effects of autologous serum
eye drops on conjunctival expression of MUC5AC. In a prospective, interventional study of various OSDs [14], 38
eyes (n = 19) were assessed pre- and postautologous serum treatment (6 weeks). The authors reported increased
MUC5AC expression which was related to conjunctival involvement (pretherapy), as well as diminished squamous
metaplasia and increased goblet cells post-therapy (p < 0.01). The researchers concluded that qPCR may be a new,
reliable and objective means to assess the efficacies of DED therapeutics. They did, however, add a caveat that much
larger patient cohorts were necessary, alongside longitudinal studies, in order to further understand the long-term
effects of autologous serum.
In terms of protein analysis, Zhang et al. [34] utilized immunolabeling of IC membranes from 66 DED subjects,
once again to assess MUC5AC, as well as the proinflammatory cytokine IL-6. This group reported lower MUC5AC
in the severe symptom group, versus mild and moderate symptom groups (both p < 0.001), while IL-6 was increased
in the severe symptom group (vs the mild and moderate symptom groups; both p < 0.001). Furthermore, a negative
correlation (p < 0.001) was noted between MUC5AC and the scores for the OSD index (OSDI, a measure of
patient-reported DED symptoms). Conversely, IL-6 was positively correlated with OSDI (p < 0.001). The authors
concluded that there was an association between reduced mucin levels and increased IL-6 levels in DED, which
correlated to severity of symptoms. These protein data appear to agree with both of the aforementioned qPCR
studies [14,33] in demonstrating reduced levels of MUC5AC in subjects with DED.
Blepharitis & meibomian gland dysfunction
Blepharitis is the general term for chronic inflammation of the eyelids [35]. The etiology of blepharitis is not
completely understood, however, as it is multifactorial in nature and usually occurs as a complication of other
conditions, such as bacterial infections, atopy, diabetes, seborrhea and some parasites, such as demodex, as well as
being associated with meibomian gland dysfunction (MGD) [36]. Extensive literature searches did not yield similar
numbers of recent IC articles specifically on blepharitis, as for other DED subtypes. Although, conjunctival IC
work by Karalezli et al. [37] on patients with seborrheic dermatitis revealed significantly fewer conjunctival goblet
cells in this group compared with healthy controls (p < 0.001). Furthermore, another study of 18 dry eye subjects
(including some with presentations of blepharitis), underwent treatment with a therapeutic ocular surface medium
(a tear replacement therapy) for up to 2 months [38]. In the randomized control trial, therapeutic ocular surface
medium was found to significantly improve the blepharitis score (p = 0.002), as well as the conjunctival IC score
(p = 0.028). While this was not conclusive evidence of a solely blepharitic/MGD group (mixed DED subtypes
were used), it does indicate studies have been performed which include this specific dry eye demographic [38].
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Another study [39] used IC and qPCR of the tarsal conjunctiva (and eyelid margin cells) to measure changes in the
inflammatory mediators IL-1β, IL-8, MMP-9 and TGF-β1 of MGD patients (n = 16) versus eight controls (pre-
and post-azithromycin therapy). In this study of patients with MGD-related posterior blepharitis and conjunctival
inflammation (n = 16) treated with azithromycin, this group found that pretreatment MGD patients revealed
significantly increased mRNA expression of IL-1β, IL-8 and MMP-9 (all p < 0.001), and significantly reduced
levels of TGF-β1 (p < 0.02), when compared with healthy subjects. Following 2 weeks of azithromycin treatment,
the mean mRNA expression of IL-1β, IL-8 and MMP-9 was significantly diminished (p < 0.001; p = 0.002 and
p < 0.001, respectively), while TGF-β1 was significantly increased (p = 0.002). After 4 weeks of azithromycin
treatment, expression of IL-1β, IL-8 and MMP-9 were further reduced or remained lower (IL-1β; p < 0.001; IL-8,
p < 0.001; MMP-9; p < 0.001), and TGF-β1 mRNA levels remained higher (p = 0.001). This study concluded
that IC is a simple and non-invasive technique to sample ocular surface cells, which permitted assessment of
pro-inflammatory mediator expression pre- and post-topical azithromycin therapy [39].
Ocular graft-versus-host disease
Graft-versus-host disease (GvHD) is a condition that may occur following a hematopoietic (stem cell i.e. bone
marrow) transplant, whereby white blood cells from the donated tissue treat the recipient’s body as foreign, and
thus immunologically attack the host’s cells. Numerous organs are affected, for example, the liver, gut, skin and
lungs, among others. Although there is an ocular–specific form, termed ocular GvHD (oGvHD), which may
precede other vital organ damage. In oGvHD, the ocular surface tissues are predominantly affected, presenting
as severe dry eye as a direct consequence of immune-mediated lacrimal gland (and conjunctival) destruction [40].
Recently, IC has also been used to assess morphological changes and novel biomarkers in subjects with oGvHD.
For example, Na et al. [41] investigated subjects with chronic GvHD following allogeneic hematological stem cell
transplantation that had been diagnosed with refractory DED. Alongside a number of other tests (including OSDI,
Schirmer, tear break-up time [TBUT], tear osmolarity and cornea staining score), IC was performed to measure
grade and goblet cell density pre- and postautologous serum therapy (4 weeks). This group reported that, as well
as improvement in the other tests, improved IC grade and goblet cells density improved from 3.4 to 2.4, and from
90.6 to 122.6 cell/mm2, respectively [41]. A similar study, albeit without autologous serum therapy, also used IC on
40 GvHD subjects with and without ocular involvement and they noted DED in 30 of the subjects and abnormal
cell morphologies in 75% of all GvHD IC samples [42]. Of those with abnormal IC, a significant number were
from subjects with oGvHD (91.7%) versus those without oGvHD (67.9%; p = 0.024). This work indicated the
utility of IC, alongside other measures (OSDI score, corneal involvement and Schirmer-I test) to ascertain levels
of ocular morbidity in GvHD. Although the authors noted that cellular abnormalities were also observed in eyes
without oGvHD.
Research by Cocho et al. [43] performed an analysis of 84 genes from IC samples of 20 oGvHD patients and
14 healthy individuals. Following exposure to standardized environmental conditions, samples were retrieved and
genes assessed via qPCR. Of these genes, 34 showed significant differences in expression. That is, in GvHD
samples, increased expression of IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ and CCL2 was noted (>sixfold);
moderate overexpression of 26 genes was demonstrated (two to sixfold), while EGFR was downregulated (2.63-
fold). Following generation of a receiver operator curve, from a panel specifically made up of EGFR, IL-6, IL-9
and NAMPT, the researchers concluded that these four genes showed the greatest potential as oGvHD diagnostic
biomarkers [43].
In terms of protein analysis, Eberwein et al. [12] has performed immunostaining of conjunctival IC membranes
for HLA-DR, cytokeratin 19 and CD8, alongside a battery of other dry eye tests, in 27 GvHD patients with dry
eye. Of these, 18 showed clinical signs of chronic oGvHD. In contrast to earlier research studies [44,45], this study
failed to demonstrate a correlation between oGvHD status and HLA-DR expression in conjunctival epithelial
cells [12]. The authors did, however, report an association between CD8-stained lymphocytes and oGvHD. Despite
a small patient cohort, the results indicated the potential of CD8 as a biomarker for severe DED, particularly in
oGvHD.
Sjögren’s syndrome-dry eye
Sjögren’s syndrome (SS) is the second most common autoimmune disease and in its primary form, SS is characterized
by immune-mediated lymphocytic infiltration of the lacrimal and salivary glands, resulting in tissue destruction
and fibrosis. Primary SS symptoms primarily present as severe dry eyes and dry mouth (xerostomia).
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Some groups have undertaken studies of patients with SS-dry eye (SS-DE), using IC, to ascertain if any
associations exist between this sampling technique and clinical findings of DED. For example, a recent study by
Mocanu et al. [46] assessed 42 subjects with SS-DE (vs 10 normals), to determine if cellular anomalies could be
correlated with clinical parameters, with a view to specifically linking IC to SS-DE severity. All subjects underwent
histopathological examination of ocular surface cells by IC of the superior conjunctiva, using cellulose acetate
filter paper (Millipore), followed by fixation of cells in 95%/1% ethanol:formalin, and periodic acid–Schiff (PAS)
staining. Those found with SS-DE were divided into four groups of DED severity (stages I-IV; of increasing
severity). This IC study revealed that normal subjects demonstrated numerous small, round epithelial cells with
a nucleus/cytoplasm ratio of 1:2 and large PAS-positive goblet cell cytoplasms. In SS-DE patients, a variety of
conjunctival epithelial morphologies were noted, depending on severity. For example, for low-grade severity, there
were slightly enlarged epithelial cells, and smaller nuclei (nucleus/cytoplasm 1:3). With increasing sicca severity,
epithelial cells were smaller and showed increasing signs of squamous metaplasia, as well as clumping of mucous.
By contrast, the goblet cells in normal subjects were abundant, oval and demonstrated intense cytoplasmic staining
for PAS. In SS-DE individuals, there was goblet cell loss and progressive epithelial cell flattening, which was
significantly different to normals (p < 0.001). The authors surmised that IC permitted rapid identification of
conjunctival changes in SS-DE, with a sensitivity of >90% and a specificity of >95% in these patients, and showed
a robust correlation between clinical severity and squamous metaplasia grade [46].
Similarly, Jirsova et al. [22] used IC on individuals with severe DED to determine levels of squamous metaplasia,
except that in this research, the effects of autologous serum on cell changes were also investigated. The patient cohort
was composed of six individuals with primary SS, six with secondary SS, one with sarcoidosis and four patients had
DED of indeterminate cause. All subjects remained on their existing DED therapy, in addition to the autologous
serum, throughout the study. The researchers measured established hallmarks of squamous metaplasia (goblet and
epithelial cell densities) and noted evident cellular changes in IC, with severity of DED. For instance, significant
increases in lower conjunctival goblet cell densities (p < 0.0001) and epithelial cells densities (p < 0.05), were
observed, while significant reductions in HLA-DR positive cells (p = 0.026), snake-like chromatin (p = 0.022)
and apoptosis (p = 0.024) were observed after 3 months of autologous serum therapy. This study illustrated the
usefulness of IC in measuring levels of squamous metaplasia in severe dry eye (including SS-DE), as well as in
monitoring response to therapeutic regimes [22].
As well as using IC to monitor squamous metaplasia in severe DED, novel SS-DE biomarkers have been identified
by gene analysis following RNA extraction from IC membranes. Recently, McNamara et al. [47] performed qPCR
for paired box protein 6 (PAX6, an embryonic transcription factor involved in ocular mucosal surface development),
IL-1β and SPRR1B (a pathological keratinization marker) on RNA from IC membranes of 43 SS-DE patients and
43 healthy controls. SS-DE patients revealed significantly reduced expression of PAX6 (p = 0.01), and PAX6 loss
was strongly correlated with the ocular staining score (p = 0.027). Moreover, this group confirmed that SPRR1B
expression was a marker for pathological keratinization (commonly seen in SS), by reporting significantly increased
expression in SS patients versus controls (p = 0.009). Of note, the authors reported that SPRR1B increases correlated
with higher ocular surface IL-1β levels (p < 0.0001). Together, these results present convincing evidence of a link
between PAX6 loss, local inflammation and squamous metaplasia in severe DED/SS-DE. Once again, gene analysis
by IC demonstrates its usefulness in confirming previous animal study data in a human setting.
Ocular allergies
Conjunctival inflammatory conditions commonly include allergy-associated conjunctival disease, and can be
grouped into conditions such as seasonal allergic conjunctivitis (SAC), vernal keratoconjunctivitis (VKC) and atopic
keratoconjunctivitis (AKC). Patients with ocular surface allergies have shown evidence of increased eosinophils,
which appear to mediate allergic conditions through release of histamine (via mast cell degranulation), as indicated
by the presence of eotaxin, a potent chemoattractant for eosinophils, in their tear fluids [48].
A unique study using IC of conjunctival and corneal cells from subjects with AKC and corneal ulcers (n = 8) was
performed by Okada et al. [49] to analyze surface characteristics and the presence of inflammatory cell infiltrates.
This group used cellulose acetate filter paper (Millipore) applied to the upper palpebral conjunctiva and corneal
ulcer, followed by counterstaining with PAS. In samples containing advanced squamous metaplasia, they noted
wide-spread invasion of eosinophils and neutrophils among ocular surface epithelial cells. As a result, the authors
suggested that this IC-based clinical evidence of inflammatory cells served to demonstrate their hostile effects on
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corneal epithelial cells undergoing squamous metaplasia in AKC. They concluded that inflammatory infiltrates
resulted in adverse effects on ocular surface cellular cohesion and integrity [49].
Another example of ocular allergy that has been investigated using IC is VKC, which is predominantly diagnosed
by signs and symptoms, with the latter presenting as itching, tearing, redness and photophobia. Though it should
be noted that these presentations are similar to other forms of allergic conjunctivitis and, within VKC, these
symptoms may vary from patient-to-patient [50]. Therefore, objective tools may be necessary to confirm a VKC
diagnosis. In recent years, pro-inflammatory mediators have been assessed by IC, in order to determine their
involvement in mediating ocular surface allergies, such as VKC. For example, a study by Shoji et al. [51] investigated
conjunctival mRNA expression of eotaxin-1, -2 and -3 in IC membranes of VKC patients (alongside tear protein
analysis by ELISA). VKC subjects (n = 25) were compared with normal healthy controls (n = 11) using reverse
transcriptase PCR and the authors reported a significantly higher positive ratio of eotaxin-1, -2 and -3 mRNA
expression (p < 0.01, p < 0.01 and p < 0.05, respectively) in the VKC group. Increased expression of this eotaxin
subgroup in VKC indicated their potential as pathophysiological biomarkers of inflammatory cell infiltrates in this
specific demographic of ocular surface allergy. While later work on VKC by Pong et al. [52] analyzed IC-derived
human conjunctival cells (alongside tear proteomic assays) and demonstrated high levels of hemopexin expression
(a class I acute-phase protein which is secreted after inflammatory events) via immunocytochemistry. Specifically
in VKC patients, they reported increased cytoplasmic hemopexin in dekeratinized conjunctival epithelium and
necrotic macrophages, but not in other inflammatory cells (eosinophils and neutrophils), thus indicating a role
for this protein in the pathology of VKC [52]. Additionally, work by Inada et al. [53] utilized IC (nitrocellulose
membranes) to analyze conjunctival epithelial cell mRNA of patients with VKC (n = 11), versus normal healthy
controls (n = 11), alongside in vitro assays. qPCR of extracted RNA was used to assess expression of IL-8, eotaxin-2
and CCL-20 (a chemokine ligand for CCR6). The authors reported that CCL-20 mRNA expression was present
in all conjunctival locations of controls. By contrast, significantly increased expression of CCL-20 was observed in
the severe VKC group, versus the mild VKC and control groups (p < 0.05). The authors surmised that CCL-20,
which is associated with inflammatory cell migration and the presence of inflammation, may mediate ocular surface
homeostasis, hence worsening of VKC presentation [52]. Similarly, a recent IC study by Shiraki et al. [54] enrolled
18 patients with VKC or AKC (and 12 healthy controls) to assess eotaxin-2 mRNA levels by qPCR. The results
showed significantly higher levels of eotaxin-2 in the active stage than for the stable stage of the AKC/VKC group
and the controls (both p < 0.01), once again indicating eotaxin-2 as a putative biomarker of the active inflammatory
stage of AKC/VKC.
Dry eye disease & other ocular conditions
Keratoconus
Keratoconus is a common degenerative and bilateral disorder that is characterized by thinning of the cornea,
resulting in corneal distortion. It presents with bulging of the cornea, giving the distinctive conical shaping
observed. Although commonly described as noninflammatory, some studies have reported impaired tear secretion
and DED in keratoconus patients [55,56]. Subsequently, a pilot study by Carracedo et al. [57] investigated keratoconus
patients (n = 15) for the presence of DED, using morphological assessment of goblet cells by IC. They found that,
when compared with healthy controls (n = 16), keratoconus patients demonstrated significantly lower densities of
goblet cells (p < 0.05), once more showing how IC may be reliably used to assist in confirming DED diagnoses.
More recently, keratoconus research has employed conjunctival IC (alongside tear osmolarity, TBUT, Schirmer
test, OSDI and ocular staining) to monitor ocular surface (and tear) changes, pre- and postcorneal collagen cross-
linking [58]. This study of 26 patients with progressive keratoconus showed statistically significant increases in
IC grading (superior and temporal; p = 0.005 and p = 0.006, respectively) at 3 months post-treatment versus
pretreatment. However, it should be noted that both studies [57,58] are preliminary and comprise small patient
numbers, therefore further studies are necessary to confirm these findings.
Thyroid orbitopathy
Thyroid orbitopathy (TO), also referred to Graves’ orbitopathy or thyroid eye disease, is an autoimmune condition
usually associated with thyroid disease, especially Graves’ disease (GD). It presents with enlarged, dysfunctional
extraocular muscles, strabismus and diplopia. Moreover, a common complication of TO is DED, which occurs due
to increased proptosis and lower lid retraction (and thus exposed ocular surfaces), resulting in incomplete blinking
and partial distribution of tears across the ocular surface. This causes enhanced evaporation of tears, hyperosmolarity
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and resultant ocular surface inflammation [59]. As a consequence of TO, it is imperative that markers of DED be
identified in order to better manage this debilitating condition. A review of the literature concerning TO, ocular
surface inflammation/DED and IC yielded a number of studies, some of which will be discussed here.
A study by Ismailova et al. [60] assessed 92 eyes from 46 patients with TO in order to ascertain morphological
changes to the ocular surface. Following ocular surface damage (DED) being identified in 56 eyes (via positive
lissamine green staining), these eyes underwent conjunctival histological analysis. Using IC, the authors reported
goblet cell loss, extreme desquamation of superficial cells and epithelial keratinization. This group concluded that,
although the conjunctival histopathological changes were consistent with DED, they were not specific for TO [60].
Similarly, Wei et al. [61] performed histopathological analysis (in vivo confocal microscopy) of IC membranes
from 15 TO subjects versus 15 controls, to investigate changes to the conjunctiva. As seen by Ismailova et al. [60],
Wei et al. [61] noted reduced bulbar conjunctival goblet cell density (superior and temporal, p < 0.004 and p < 0.01,
respectively), as well as significantly increased squamous metaplasia in the TO group (both superior and temporal,
p < 0.001). Moreover, the latter study found significantly lower levels of superficial epithelial cell density in the
superior bulbar conjunctiva, versus controls (p = 0.002). Both studies appear to endorse the fact that IC can
be used to confirm a clinical diagnosis of DED in patients with TO [60,61]. The question remains as to whether
these findings are specific to TO and so this may be where the identification of other biomarkers of ocular surface
inflammation, that are specific to the condition, comes into play.
As an example, Pawlowski et al. [62] undertook an IC and flow cytometric-based study of the previously described
conjunctival epithelial cell inflammatory markers, HLA-DR and ICAM-1, in 10 subjects with active TO, versus
15 subjects with GD (without active TO) and 10 healthy controls. PES membranes were applied to the superior
and superior-temporal bulbar conjunctiva and underwent cell extraction for flow cytometric analysis. Of interest,
this group demonstrated a significant increase in HLA-DR positive conjunctival epithelial cells with active TO,
versus GD without active TO and healthy controls (both p < 0.005). Furthermore, conjunctival epithelial cells
from active TO patients showed significant increases in ICAM-1 versus controls (p < 0.005). While patients with
GD without active TO showed no increase in ICAM-1 expression, versus controls. These data indicate putative
roles for both HLA-DR and ICAM as specific biomarkers of TO-associated ocular inflammation [62].
Recent work by Hsu et al. [15] utilized immunostaining of IC membranes to evaluate dry eye as a result of TO.
Using immunofluorescence, membranes were stained for a number of DED-related pro-inflammatory cytokines,
including IL-1α, IL-1β and IL-6. All subjects with TO-associated DED showed positive staining for these cytokines.
Of interest was the finding that a trend occurred between the clinical inflammatory score and immunological IC
grade, indicating these cytokines as potential biomarkers and/or therapeutic targets of TO-related dry eye. Although
further research is needed to validate the findings of the latter two studies [15,62], the initial data are promising.
Impression cytology & systemic conditions associated with dry eye disease
It should be noted that in recent years, IC has been used increasingly in the diagnosis of DED as a complication of
systemic disease, such as cystic fibrosis (CF), psoriasis and colitis.
Cystic fibrosis
Although CF is a hereditary disease, subjects may be affected by DED presentations as this disorder influences
all secretory epithelia, including those in the eye. Early work by Mrugacz et al. [63] used IC and flow cytometry
to assess the aforementioned inflammatory marker HLA-DR in conjunctival epithelial cells from patients with
CF (n = 25) versus healthy controls (n = 25). This unique study demonstrated, for the first time, a significantly
increased HLA-DR expression on CF patient conjunctival epithelial cells, versus normals (p = 0.0019). Moreover,
the authors showed significant reductions in tear production and tear quality in CF patients (p < 0.001 and
p < 0.0001, respectively) which, in combination, indicates an unstable tear fluid and resultant ocular surface
inflammation. A subsequent study by this group [64] used IC to assess ocular surface health of CF patients. The
authors reported a significant increase in squamous metaplasia grade in this specific patient demographic, versus
controls (p = 0.00013). Additionally, CF subjects revealed significantly lower average goblet cell densities than
in the control groups (p < 0.001), while inflammatory cells (neutrophils) were noted in four CF patients [64].
The additional information, which provided evidence of neutrophil infiltrates, also served to confirm the already-
established inflammatory nature of dry eye, regardless of the underpinning primary disorder. The authors concluded
that IC helped provide useful clues to the pathological changes in ocular surface cells of CF patients, which could
be used to observe progression (and/or response to therapeutics) in DED of this specific patient cohort.
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Psoriasis
Psoriasis is a chronic autoimmune disease that primarily affects the skin, resulting in patches of a red, scaly rash,
found on the scalp, ears, elbows and knees. In addition, psoriasis may present with ocular symptoms, specifically
of the anterior segment [65]. Manifestations may include dry eye, conjunctivitis and blepharitis. To date, only two
studies have employed IC to assess conjunctival cell morphological changes in psoriasis-associated DED [66,67].
However both studies have yielded important information. In 1999, Karabulut et al. [66] assessed 50 individuals
with chronic plaque psoriasis and compared them to 50 healthy volunteers and reported that 50% of the psoriasis
subjects had a grade 0, 30% had a grade I and 20% had a grade II conjunctival IC differentiation, versus 95%, 3%
and 2%, respectively for controls (p < 0.001). In addition, a snake-like appearance of nuclear chromatin cells was
noted more commonly in eyes in the psoriasis group. Together, the use of IC served to identify early morphological
changes to the conjunctiva in this patient group. A more recent study in 2013 [67] assessed 30 patients with chronic
plaque psoriasis and 30 healthy controls via IC. The authors reported significant conjunctival cellular changes, as
well as diminished goblet cell density (p < 0.001) compared with controls (p = 0.003). Thus, both studies showed
significant morphological changes to the conjunctiva and ocular surface degeneration, leading to dry eye, in those
with psoriasis.
Colitis & coeliac disease
Finally, a recent study by Oltulu et al. [68] employed IC (nitrocellulose acetate) to assess DED associated with
ulcerative colitis (UC). UC is a chronic condition which manifests as colonic mucosal inflammation and ulceration.
This disorder also presents with numerous ocular complications, including dry eye, blepharitis, episcleritis and
anterior uveitis [69]. In this novel study, samples from patients with UC (n = 15) were compared with healthy
controls (n = 15). IC of the conjunctiva revealed a statistically significant difference (p < 0.05) in distribution
of IC grades between the two groups. This group also showed significantly lower tear production and tear quality
(Schirmer-I test and TBUT test) in patients with UC compared with the controls. This is the first study of its kind
to show compromises to the tear fluid and conjunctival cells in subjects with inflammatory bowel disease, further
confirming the usefulness of IC in diagnosis and monitoring of systemic disease-associated dry eye [69].
Similarly, research by Uzel et al. [70] used IC to assess ocular surface changes in coeliac disease (CD). CD is
an immune-mediated inflammatory condition of the small intestine that is triggered by dietary intake of gluten.
In this study, IC was performed on 56 eyes of 28 patients with CD versus 58 eyes of 29 healthy controls. A
significant difference in IC grades between the two groups (p = 0.001) was observed. Moreover, patients with CD
disease presented with larger conjunctival epithelial cells and fewer goblet cells. Thus CD appears to be related to
morphological changes of the ocular surface which may present as dry eye. Both studies are unique in presenting
such data and indicate a new area of research involving the use of IC which may shed light onto the ocular
dysfunction associated with inflammatory bowel disease [70,71].
Conclusion
From the literature reviewed, it can be seen that IC has the potential to provide detailed cytological data in
confirming a diagnosis of squamous metaplasia/dry eye, both in OSDs and in systemic diseases with an ocular
involvement. In addition, vast improvements in the sensitivities of available gene and protein assays have allowed
identification of a number of putative biomarkers that require further investigation.
Thus, the advantages of IC are:
 Much less invasive than conjunctival biopsies, scraping or brush cytology.
 Specific (or multiple) conjunctival areas can be sampled.
 Morphological data can be elucidated alongside biomarkers analysis.
 No disruption to the basement membrane.
 Provides a biochemical ‘snapshot’ of the tissue at that point in the disease course.
It should also be noted that IC also has a number of limitations, including:
 A lack of standardization in the methodology used (i.e., membrane type used, fixation procedures, areas sampled
and processing/extraction techniques).
 Sampling is usually restricted to the outermost tissue layers.
 The effects of topical anesthetics on subsequent assays (e.g., qPCR) have not been fully examined.
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 Direct RNA/protein extraction of whole membranes may not permit identification of the exact cellular source
of biomarkers (i.e., goblet or epithelial cells, or inflammatory cell infiltrates).
In summary, for systemic disease-related DED, it will be interesting to see if future IC studies identify specific
biomarkers for each of the conditions reviewed here (e.g., cytokines and other immune mediators), to permit
improved diagnosis, stratification and therapeutic surveillance, or if there are similarities to DED biomarkers
of nonsystemic origin. Research within our group has indicated substantial inhibition of qPCR components,
following IC retrieval after topical anesthetics [aganet al. Unpublished ]. Therefore future studies, including
the optimization of standard operating procedures for qPCR, should first be undertaken in order to address this
potentially confounding factor. As with tear fluid biomarker analysis [72], it is anticipated that future IC studies
comprising larger patient cohorts, more strict stratification of recruited patients, improved assay sensitivities and
standardized methodologies will all serve to enhance the diagnosis, monitoring and treatment of disorders of the
ocular surface.
Future perspective
It can be seen that in the last decade, the utilization of IC in assessing ocular surface changes in DED have
dramatically increased. Not only have studies presented evidence of histopathological changes to the conjunctiva,
but improved sensitivities of protein-based and gene-based analysis have allowed the discovery of several putative
biomarkers. Previous reviews have indicated the use of ocular surface tissues, including tears, for direct assessment
of ocular diseases in directing personalized medicine [70,71]. It is therefore anticipated that further identification of
other, more specific, biomarkers will lead to an improved understanding of the mechanisms underlying DED, as
well as providing novel therapeutic targets for this complex and multifactorial disease.
Executive summary
Impression cytology & ocular surface disease
 With ageing global populations, early diagnosis of ocular surface disease is necessary to avoid reduced quality of
life and productivity.
 In the field of personalized medicine, impression cytology (IC) has the potential to confirm clinical diagnoses of
ocular surface disease.
Dry eye disease & other ocular conditions
 Several groups of biomarkers for dry eye disease have been identified by IC, including cytokines, mucins and
inflammatory markers which may also provide therapeutic targets.
 In keratoconus, studies have shown HLA-DR, ICAM-1 and cytokines as putative biomarkers.
Impression cytology & systemic conditions associated with dry eye disease
 In subjects with systemic diseases cystic fibrosis, colitis and coeliac disease, changes to the conjunctival epithelium
have been reported.
 However, as this is a new area of research, more specific cellular biomarkers have yet to be identified.
Conclusion
 IC represents a rapid, user-friendly technique for retrieving ocular surface cells for gene and protein analysis.
 Future, more standardized, studies are necessary to delineate biomarkers specific to systemic disease with ocular
involvement.
Financial & competing interests disclosure
S Hagan is employed by GCU, Scotland, UK, is a lecturer and PI in Vision Sciences in the Department of Life Sciences at GCU, with
a special interest in predictive and prognostic biomarkers of ocular surface disease. The author has no other relevant affiliations
or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or
materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/4.0/
1144 Biomark. Med. (2017) 11(12) future science group
Biomarkers of ocular surface disease using impression cytology Review
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Thatcher RW, Darougar S, Jones BR. Conjunctival impression cytology. Arch. Ophthalmol. 95, 678–681 (1977).
2. Egbert PR, Lauber S, Maurice DM. A simple conjunctival biopsy. Am. J. Ophthalmol. 84, 798–801 (1977).
•• One of the primary and original publications in the area of impression cytology (IC).
3. Nelson DJ, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch. Ophthalmol. 101,
1869–1872 (1983).
4. Doughty MJ. Objective assessment of conjunctival squamous metaplasia by measures of cell and nucleus dimensions. Diagn.
Cytopathol. 39(6), 409–423 (2011).
• A study on the utility of IC in accurately measuring cell:nucleus ratios in the diagnosis of squamous metaplasia.
5. Danjo Y, Watanabe H, Tisdale AS et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest. Ophthalmol. Vis.
Sci. 39(13), 2602–2609 (1998).
6. Pastor S, Rodriguez-Prats JL, Walewska-Szafran A, Rodriguez AE, Alio JL. Conjunctival impression cytology for the diagnosis, follow-up
and treatment in a patient with severe keratoconjunctivitis caused by alkali injury. Cornea 28(7), 817–820 (2009).
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